Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy

MaxCyte gets green light for solid tumour cell therapy. Its first CAR therapy will be tested in patients with ovarian cancer. ... The trial will test MaxCyte’s first wholly-owned CAR therapy MCY-M11 in patients with relapsed/refractory ovarian cancer

Latest news

More from news
Approximately 35 fully matching, plus 141 partially matching documents found.

Latest Intelligence

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

  • AI’s potential in the pharma life cycle AI’s potential in the pharma life cycle

    Proactive intervention. Already AI is being used to identify women whose Twitter posts indicate they may have increased risk of developing two relatively rare diseases: ovarian cancer and cervical cancer.

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

  • Deal Watch May 2016 Deal Watch May 2016

    Prima has partnered its immuno-oncology CVac in ovarian cancer by transferring its CVac related assets, including manufacturing protocols, clinical data, patents and know‐ how plus certain assets e.g. ... 110. CSPC Pharmaceutical/ Watson [Allergan].

  • Deal Watch April 2016 Deal Watch April 2016

    The explanation for this is that Janssen are getting rights only for prostate cancer, not ovarian and breast cancer where the product is in phase III and the rights do not ... 500. Tesaro (US). Janssen (US). License and collaboration. Niraparib PARP

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics